Abstract:157Gd (natural abundance = 15.7%) has the highest thermal neutron capture cross section (σ) of 254,000 barns (1 barn = 10-28 m2) among stable (nonradioactive) isotopes in the periodic table. Another stable isotope, 155Gd (natural abundance = 14.8%), also has a high σ value of 60,700 barns. These σ values are higher than that of 10B (3840 barns, natural abundance = 19.9%), which is currently used as a neutron-absorbing isotope for boron neutron capture therapy agents. Energetic particles such as electrons and γ-rays emitted from Gd-isotopes after neutron beam absorption kill cancer cells by damaging DNAs inside cancer-cell nuclei without damaging normal cells if Gd-chemicals are positioned in cancer cells. To date, various Gd-chemicals such as commercial Gd-chelates used as magnetic resonance imaging contrast agents, modified Gd-chelates, nanocomposites containing Gd-chelates, fullerenes containing Gd, and solid-state Gd-nanoparticles have been investigated as gadolinium neutron capture therapy (GdNCT) agents. All GdNCT agents had exhibited cancer-cell killing effects, and the degree of the effects depended on the GdNCT agents used. This confirms that GdNCT is a promising cancer therapeutic technique. However, the commercial Gd-chelates were observed to be inadequate in clinical use because of their low accumulation in cancer cells due to their extracellular and noncancer targeting properties and rapid excretion. The other GdNCT agents exhibited higher accumulation in cancer cells, compared to Gd-chelates; consequently, they demonstrated higher cancer-cell killing effects. However, they still displayed limitations such as poor specificity to cancer cells. Therefore, continuous efforts should be made to synthesize GdNCT agents suitable in clinical applications. Herein, the principle of GdNCT, current status of GdNCT agents, and general design strategy for GdNCT agents in clinical use are discussed and reviewed.

Functional gadolinium-based nanoscale systems for cancer theranostics

Engineered gadolinium-based nanomaterials as cancer imaging agents

Gadolinium‐based Contrast Agents for Magnetic Resonance Cancer Imaging

Gadolinium-based contrast agents for tumor targeting imaging

Gadolinium Oxysulfide-Coated Gold Nanorods with Improved Stability and Dual-Modal Magnetic Resonance/photoacoustic Imaging Contrast Enhancement for Cancer Theranostics.

Nanoscale Functional Biomaterials for Cancer Theranostics.

Gadolinium Loaded Nanoparticles in Theranostic Magnetic Resonance Imaging.

Functionalization of bismuth sulfide nanomaterials for their application in cancer theranostics

Nanomaterials Incorporated Ultrasound Contrast Agents for Cancer Theranostics

Rationally Designed Monodisperse Gd2O3/Bi2S3 Hybrid Nanodots for Efficient Cancer Theranostics

Gadolinium-based Nanoscale MRI Contrast Agents for Tumor Imaging

BSA-Bioinspired Gadolinium Hybrid-Functionalized Hollow Gold Nanoshells for NIRF/PA/CT/MR Quadmodal Diagnostic Imaging-Guided Photothermal/Photodynamic Cancer Therapy.

Gadolinium Neutron Capture Therapy (GdNCT) Agents from Molecular to Nano: Current Status and Perspectives

Gadolinium-doped hollow CeO 2 -ZrO 2 nanoplatform as multifunctional MRI/CT dual-modal imaging agent and drug delivery vehicle.

Gold Nanostar‐based Complexes Applied for Cancer Theranostics

Single Doping for Triple Functions: Integrated Theranostic Nanoplatforms for Multimodal Image‐Guided Tumor Therapy

Recent Progress in Gold-derived Nanomaterials for Tumor Theranostics

Cathepsin B-responsive and gadolinium-labeled branched glycopolymer-PTX conjugate-derived nanotheranostics for cancer treatment

Biofunctional Magnetic Hybrid Nanomaterials for Theranostic Applications.

Gold Nanoparticles in Cancer Theranostics

Advances in cancer theranostics using organic-inorganic hybrid nanotechnology